The arrival of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable interest within the healthcare community. This innovative dual GIP and GLP-1 receptor medication seems to provide impressive improvements in fat reduction compared to existing therapies. Initial patient data have indi